By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

In a sudden reversal, the US Food and Drug Administration has agreed to review Moderna’s experimental mRNA influenza vaccine.

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

In an experimental trial, a personalized mRNA vaccine was tested in 14 individuals with an aggressive form of breast cancer. It trained immune cells to target cancer-specific mutant proteins, inducing ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...